Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)

Mass General Brigham

Status and phase

Completed

Phase 1

Conditions

Recurrent Respiratory Papillomatosis

Treatments

Drug: Saline

Drug: Avastin® (bevacizumab)

Study type

Interventional

Funder types

Other

Identifiers

NCT01020747

VC-P001

Details and patient eligibility

About

This phase I single center open labeled study is planned to assess the safety and tolerability of bevacizumab for treating patients with bilateral Recurrent Respiratory Papillomatosis (RRP). Approximately 20 patients will receive bevacizumab directly injected into the vocal folds. Patients who enroll in the protocol will be injected with bevacizumab in one vocal fold that represents the more diseased of the two folds. A sham injection with saline will be administered to the other vocal fold as the control. This therapy will be administered once every 6 ± 1 week for 6 months, with the same vocal fold selected for the initial treatment always getting the drug injection. The investigator will also treat lesions by laser photoangiolysis of both vocal folds using the 532 nm potassium-titanyl-phosphate (KTP) laser.

Enrollment

20 patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female patients with dysphonia that have been diagnosed with Recurrent Respiratory Papillomatosis (RRP) of the vocal folds
Age between 18 and 60 years old
Female patients must be surgically sterilized, postmenopausal, or employ adequate contraception. Criteria for menopause are surgical menopause (hysterectomy, oophorectomy) or age > 45 years with absence of menses for greater than 12 months and an elevated serum Hormone, follicle-stimulating (FSH) (> 25 mIU/mL). Tubal ligation with menses within the past 12 months is not considered to be surgical sterilization.
Have bilateral glottal papillomatosis (i.e., involving both the right and left vocal folds)
Willing and able to comply with the investigational nature of the study and able to communicate well with investigators.
Ability to comprehend and willingness to provide written informed consent in accordance with institutional and regulatory guidelines.

Exclusion criteria

Have known sensitivity to bevacizumab
Have been treated systemically with bevacizumab within 4 months (approximately 6 half-lives).
Have hematocrits < 30, elevated PT or PTT levels more than 1.2 X the upper limit of normal (ULN) or absolute platelet counts below the lower limit of normal (LLN).
Have absolute neutrophil counts below 1500
Have urine dipsticks positive for ≥3+ proteinuria will have spot urine collections and those patients with urine protein to urine creatinine ratios greater than 1.5.
Have a history of congestive heart failure, angina that remains symptomatic despite medications, myocardial infarction or coronary artery disease-related procedure within the past 6 months (including angioplasty, stent placement, bypass graft surgery) or who have prosthetic heart valves.
Have significant uncontrolled hypertension (systolic blood pressure above 160 and/or diastolic blood pressure above 100).
Have had surgeries within 1 month of enrollment or who have un-healed surgical incisions at screening.
Have a history of thromboembolic events, gastro-intestinal (GI) ulcer or bleeding, or with a history of wound dehiscence.
Female patients that are pregnant, nursing or plan to nurse during the up to 18 months of treatment period.
Patients with a history of bleeding disorders, documented platelet dysfunction, current use of anti-platelet drugs, or abnormal prothrombin time (PT) or activated partial thromboplastin timea (PTT) laboratory values as defined in number 3 above.